Skip to content
Clinical Trials – home

Universita Degli Studi Di Brescia

Verified siteinfo

Italy Piazzale Spedali Civili 1, 25123 Brescia, Italy

  • 172 trials recruiting
  • Acute myeloid leukaemia · Dementia Alzheimer's type · Non-small cell lung cancer
  • Adults and children

About Specializations

Universita Degli Studi Di Brescia in Brescia, Italy specialises in clinical trials of conditions such as Acute myeloid leukaemia, Dementia Alzheimer's type, Non-small cell lung cancer, Plasma cell myeloma, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Dermatologic Cancer Research

At Universita Degli Studi Di Brescia, clinical research in neoplasms focuses on skin cancer and related precancerous conditions, especially actinic keratosis and cutaneous squamous cell carcinoma. These studies are designed to assess how well treatments can reduce cancer risk, improve disease control, and support better long-term outcomes for patients.

  • Evaluating treatment effectiveness in actinic keratosis and preventing progression to invasive disease
  • Studying adjuvant therapy strategies for high-risk cutaneous squamous cell carcinoma
  • Assessing whether new approaches can improve disease-free survival after standard cancer care

This work reflects a strong interest in both early skin lesion management and more advanced cancer treatment, with the goal of improving outcomes in dermatologic oncology.

Respiratory Medicine and Critical Care Studies

Research in respiratory tract diseases at the Divisione di Pediatria includes studies of acute respiratory distress syndrome, a serious condition that can affect breathing and recovery in critically ill patients. The trials aim to explore new ways to reduce complications and improve survival-related outcomes.

  • Testing therapies intended to improve lung recovery in acute respiratory distress syndrome
  • Measuring whether treatment can increase time free from mechanical ventilation
  • Exploring options that may help prevent longer-term respiratory damage

These studies are centered on better supportive care and treatment effectiveness for patients facing severe respiratory illness.

Immune System and Rare Disease Investigations

The site also supports research into immune system processes and rare inherited conditions such as WHIM syndrome. This area of work focuses on strengthening immune function, reducing infections, and understanding whether targeted treatment can offer lasting benefit for people with complex immune disorders.

  • Examining treatments that may raise circulating neutrophil levels in WHIM syndrome
  • Assessing long-term safety and tolerability in a rare immune condition
  • Supporting better control of infections and immune-related symptoms

These trials highlight a translational approach to rare disease care, combining symptom improvement with broader immune support.

Mixed Therapeutic Research Across Pediatric and Clinical Care

Across its clinical trial portfolio, Universita Degli Studi Di Brescia is contributing to research that spans oncology, respiratory disease, skin disorders, and immunology. The studies are broadly aimed at testing new therapies, comparing treatment options, and improving how clinicians manage both common and rare diseases.

  • Comparing active treatment with placebo or standard care to clarify benefit
  • Investigating whether new interventions can improve patient outcomes and safety
  • Supporting evidence-based care for both chronic and severe conditions

With 7 trials and a large investigator network, the site shows an active commitment to advancing clinical research in multiple therapeutic areas.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Piazzale Spedali Civili 125123 BresciaItaly
Recruiting now
172 trials
Conditions studied
291
Partner status
Verified site

More sites in BresciaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

509 clinical trials

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Eczema nummular

Recruiting

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Visugromab
  • Sponsor:CatalYm GmbH

A study testing xanomeline tartrate and trospium chloride for treating agitation in patients with Alzheimer's disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Vitiligo

Recruiting

Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Schizophrenia

Recruiting

Study of evenamide as add-on treatment for patients with treatment-resistant schizophrenia not adequately controlled by current antipsychotic medications

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Evenamide
  • Sponsor:Newron Pharmaceuticals S.p.A.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.